This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Produkteigenschaften
- Artikelnummer: 9783030098179
- Medium: Buch
- ISBN: 978-3-030-09817-9
- Verlag: Springer International Publishing
- Erscheinungstermin: 02.02.2019
- Sprache(n): Englisch
- Auflage: Softcover Nachdruck of the original 1. Auflage 2018
- Serie: Resistance to Targeted Anti-Cancer Therapeutics
- Produktform: Kartoniert, Paperback
- Gewicht: 406 g
- Seiten: 242
- Format (B x H x T): 155 x 235 x 15 mm
- Ausgabetyp: Kein, Unbekannt